Triple threat: new malaria cocktail aims to outsmart resistance

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female, aged ≥6 months to \<12 years (For Gambia, Rwanda sites only: ≥6 months) * Ability to take oral medication * Acute uncomplicated P. falciparum monoinfection * Asexual P. falciparum parasitaemia: 1,000/µL to ≤10% parasitaemia, determined on a peripheral blood film (At Gambia, Rwanda sites only: For subjects ≥12 years - 1000/µL to 200,000/µL) * Fever defined as ≥ 37.5°C tympanic temperature or a history of fever within the last 24 hours * Written informed consent by the subject or by parent/guardian in case of children lower than the age of consent and assent if required (per local regulations) * Willingness and ability of the subjects or parents/guardians to comply with the study protocol for the duration of the study Exclusion Criteria: * Signs of severe malaria (adapted from WHO criteria) * Patients not fulfilling criteria for severe malaria but with another indication for parenteral antimalarial treatment at the discretion of the treating physician * Haematocrit \<15% at screening (For Gambia, Rwanda sites only: For subjects ≥12 years - Haematocrit \<20% at screening) * Subjects who have received artemisinin or a derivative within the previous 7 days OR lumefantrine or amodiaquine within the previous 14 days OR mefloquine or piperaquine within the previous 30 days * In applicable countries: use of seasonal malaria chemoprophylaxis (SMC) within the last 14 days. * Acute illness other than malaria requiring systemic treatment * Severe acute malnutrition (in Niger only - only those patients with Severe Acute Malnutrition and complications requiring inpatient nutritional treatment will be excluded) * Known HIV infection * Known tuberculosis infection * For females: post-menarche (For Gambia, Rwanda sites only: females who are pregnant, trying to get pregnant or are lactating) * History of allergy or known contraindication to any of the study drugs, including neuropsychiatric disorders and epilepsy * Previous splenectomy * Enrolment in DeTACT in the previous 3 months * Participation in another interventional study in the previous 3 months